

HANDLE ORDINARY
ISSUES BEFORE THEY
GET OUT OF HAND



RULE OUT ***H. PYLORI***
INFECTION TODAY

Discover
more:



HEALTHY
STOMACH
INITIATIVE

This material has been endorsed by
HSI, a prominent group of well-known
gastroenterology specialists from 80
countries.

 **JUVISE**®
pharmaceuticals

H. pylori infection is a common threat^{1,2}

Helicobacter pylori (*H. pylori*) was first discovered in 1982 by Warren and Marshall^{2,3}

It is a gram-negative curved rod or s-shaped bacterium that infects the gastric mucosa²

It was classified as a carcinogen by the World Health Organization (WHO) in 1994⁴




H. pylori infection appears to be acquired throughout life, but commonly starts in infancy⁵

Routes of transmission include
■ faecal-oral, oral-oral (dental),
gastro-oral and sexual behaviour⁵

Once a person acquires *H. pylori* infection, the bacteria usually persists throughout their lifetime²

ALMOST 50% OF ADULTS ARE INFECTED BY *H. PYLORI* WORLDWIDE¹

Global prevalence (%) of *H. pylori* infection in adults by WHO regions⁶




Adapted from: Chen YC, et al. 2024⁶

H. pylori prevalence can also vary depending on age, associated diseases, geographic regions, race/ethnicity, socioeconomic status, and hygienic conditions²

Infection can have severe consequences^{2,7,8}

After several weeks or months of infection, 100% of patients infected by *H. pylori* will develop gastritis^{2,7}

H. PYLORI-ASSOCIATED GASTRITIS IS THE UNDERLYING CAUSE OF ALMOST ALL GASTRIC DISEASES⁷



Adapted from: Asaka M, et al. 2014⁷


Gastric cancer is the fourth leading cause of cancer-related deaths worldwide⁹

H. pylori is considered the most common etiologic agent of infection-related cancers¹⁰

H. PYLORI REMAINS A MAJOR GLOBAL HEALTH PROBLEM¹¹

Symptoms of *H. pylori* can include **alarm** and **non-alarm symptoms**^{2,12}

DYSPEPSIA SYMPTOMS¹³



ALARM SYMPTOMS INCLUDE:^{2,12}

- Anaemia
- Black stools/blood in stools
- Vomiting
- Dysphagia
- Jaundice
- Unintentional weight loss

Alarm symptoms can indicate possible serious disease¹²

Patients who should trigger *H. pylori* testing^{2,14}

According to international guidelines, the following patient profiles should be investigated for *H. pylori*:^{2,14}



Dyspeptic patients *with or without alarm symptoms*



Patients *with long-term PPI use*



Patients *with active or history of peptic ulcer disease*



Patients *with a family history of gastric cancer*



Immigrants *from areas with a high prevalence of *H. pylori* infection*



Naïve patients starting long-term NSAID therapy




High-risk patients already on long-term aspirin

Non-invasive testing can help get a rapid handle on *H. pylori* infection^{2,14}

PATIENTS AGED <50 YEARS WITH DYSPEPSIA^{2,14}



NON-INVASIVE TESTS FOR *H. PYLORI*²



PATIENTS AGED ≥50 YEARS WITH DYSPEPSIA OR AT ANY AGE WITH ALARM SYMPTOMS^{2,14}

ALARM SYMPTOMS:^{2,12}

- Dysphagia
- Anaemia
- Jaundice
- Black stools/blood in stools
- Unintentional weight loss
- Vomiting



ENDOSCOPY



H. PYLORI-POSITIVE



TREATMENT SOLUTIONS¹⁴
FOR *H. PYLORI*-POSITIVE

Protect your dyspeptic patients by testing them for *H. pylori*^{2,14}



- *H. pylori* is a common gastric pathogen, which **infects almost 50% of adults worldwide**¹
- *H. pylori* infection **leads to chronic inflammation and gastritis**, which can develop into dyspepsia, peptic ulcer, gastric MALT lymphoma, or gastric cancer^{2,7,8}
- **Patients with dyspepsia, with or without alarm symptoms**, should undergo testing for *H. pylori* infection^{2,14}
- Multiple **non-invasive tests** with high specificity and sensitivity **are available for rapid *H. pylori* infection diagnosis**²

CI, confidence interval; MALT: mucosa-associated lymphoid tissue; NSAID, non-steroidal anti-inflammatory drug; PCR: polymerase chain reaction; PPI: proton-pump inhibitor; UBT: urea breath test; WHO: World Health Organization.

1. Zamani M, et al. *Aliment Pharmacol Ther*. 2018;47:868-876. 2. Malfetheriner P, et al. *Nat Rev Dis Primers*. 2023;9:19. 3. Warren JR, et al. *Lancet*. 1983;1:1273-1275. 4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. *IARC Monogr Eval Carcinog Risk Hum*. 1994;61:177-241. 5. Charitos IA, et al. *Gastroenterol. Insights*. 2021; 12:111-135. 6. Chen YC, et al. *Gastroenterology*. 2024;166:605-619. 7. Asaka M, et al. *J Gastroenterol*. 2014;49:1-8. 8. Malik TF, Gnanapandithan K, Singh K. *Peptic Ulcer Disease*. [Updated 2023 Jun 5]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. <https://www.ncbi.nlm.nih.gov/books/NBK534792/>. [Last accessed December 2024]. 9. Sung H, et al. *CA Cancer J Clin*. 2021;71:209-249. 10. Wroblewski LE, et al. *Clin Microbiol Rev*. 2010;23:713-39. 11. Katelaris P, et al. *J Clin Gastroenterol*. 2023;57:111-126. 12. Meineche-Schmidt V, et al. *Scand J Prim Health Care*. 2003;21:224-9. 13. Harer KN, et al. *Gastroenterol Hepatol (N Y)*. 2020;16:66-74. 14. Malfetheriner P, et al. *Gut* 2022;71:1724-1762.